
Beyond Air, Inc.
97
Recent developments highlight narrowing losses driven by sales growth, FDA breakthrough device designation for LungFit GO, ongoing earnings calls providing operational updates, and initiation of coverage by Lake Street with a buy recommendation.
- Beyond Air reported narrowing Q3 loss with sales rise and maintained sales outlook while awaiting FDA approval for next-generation LungFit PH device [N1].
- The company received FDA Breakthrough Device Designation for LungFit GO in nontuberculous mycobacteria pulmonary disease (NTM-PD) [N4].
- Lake Street initiated coverage of Beyond Air with a buy recommendation in September 2026 [N3].
- Recent earnings call transcripts for Q2 2027 and Q1 2027 provide updates on commercial progress and clinical development [N2, N5].
- Q4 2026 earnings call transcript reflects ongoing operational activities and market engagement [N7].
Beyond Air, Inc. develops and commercializes nitric oxide (NO) generator and delivery systems under the LungFit® platform, which produces NO from ambient air for therapeutic use. Its first FDA-approved product, LungFit® PH, treats persistent pulmonary hypertension of the newborn (PPHN) and has CE mark approval for additional indications including peri- and post-operative pulmonary hypertension in pediatric and adult patients. The company is advancing next-generation devices such as LungFit® PH II, designed for portability and transport use. Beyond Air also pursues treatments for viral lung infections (LungFit® PRO) and nontuberculous mycobacteria lung disease (LungFit® GO), with ongoing clinical trials. Additionally, it holds majority ownership in affiliates Beyond Cancer, Ltd. and NeuroNOS Limited, targeting oncology and neurological conditions respectively. The company has established regulatory approvals and distribution agreements across multiple countries and markets its products primarily in the U.S. and internationally.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide delivery systems, primarily through its LungFit® platform. The company has FDA and CE approvals for its LungFit® PH device treating persistent pulmonary hypertension of the newborn and is developing additional products targeting viral lung infections and nontuberculous mycobacteria lung disease. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, the company reported $5.4 million in cash and equivalents, $5.7 million in short-term investments, a current ratio of 3.67, and a net loss of $7.8 million for the quarter [S2]. Recent news includes narrowing losses on sales rise and FDA breakthrough device designation for LungFit GO [N1, N4].
Beyond Air's LungFit® platform addresses significant unmet medical needs in pulmonary hypertension, viral lung infections, and nontuberculous mycobacteria lung disease, with FDA and CE approvals supporting commercial launch and expansion. The next-generation LungFit® PH II device offers enhanced portability, potentially increasing market penetration. Clinical trials for LungFit® PRO and LungFit® GO show promising safety and efficacy signals, supporting further development. The company's majority ownership in affiliates targeting oncology and neurological disorders diversifies its pipeline. Regulatory approvals in over 27 countries and distribution agreements covering more than 40 countries provide a broad commercial footprint. Recent narrowing losses and sales growth indicate operational progress [N1, N4].
Beyond Air faces risks related to regulatory approvals for its pipeline products beyond LungFit® PH, including LungFit® PRO and LungFit® GO, which remain in clinical development. The company reported net losses and negative earnings per share, reflecting ongoing investment and operational costs. Nasdaq listing compliance has required multiple reverse stock splits, and the company remains under a discretionary panel monitor, indicating potential liquidity and market price risks. Market adoption of novel NO delivery systems may be challenged by incumbent therapies and reimbursement environments. Clinical trial terminations and delays, such as the U.S. trial termination for LungFit® PRO, highlight development uncertainties. The company's financial position and ability to sustain operations depend on successful commercialization and capital access.
Beyond Air's competitive advantages stem from its patented plasma pulse technology enabling on-demand generation of nitric oxide from ambient air, eliminating the need for high-pressure cylinders and cumbersome safety procedures common in traditional NO delivery systems. Its LungFit® PH device is the first FDA-approved and CE-marked system using this technology, providing a unique product in the pulmonary hypertension treatment market. The company's expanding regulatory approvals and distribution agreements across over 40 countries enhance market access. Additionally, its diversified pipeline targeting severe lung infections, viral pneumonia, and neurological conditions through affiliated companies broadens its therapeutic reach. The proprietary technology and regulatory clearances create barriers to entry for competitors in this specialized medical device and biopharmaceutical space.
• Regulatory and Clinical Development Risks: Beyond Air's pipeline products require successful completion of clinical trials and regulatory approvals. Delays or failures could impact commercialization prospects.
• Financial and Liquidity Risks: The company reported net losses and negative EPS, with limited cash reserves. Maintaining Nasdaq listing compliance and securing capital are ongoing challenges.
• Market Adoption and Competitive Risks: Adoption of LungFit® devices depends on acceptance by healthcare providers and payers amid competition from established NO delivery systems.
• Nasdaq Listing Compliance Risks: Multiple reverse stock splits and a discretionary panel monitor indicate risks of delisting, which could adversely affect liquidity and investor confidence.
Business trends: Expansion of LungFit® platform approvals and commercial presence, clinical development in viral and NTM lung infections, and diversification through affiliates.
Execution milestones: FDA approval and launch of LungFit® PH II, completion of pivotal clinical trials, and securing additional regulatory clearances and distribution agreements.
Key risks: Regulatory and clinical development uncertainties, financial and liquidity constraints, market adoption challenges, and Nasdaq listing compliance risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems called the LungFit® platform that generates NO from ambient air [S1].
- The company's first device, LungFit® PH, received FDA premarket approval in June 2022 for treatment of persistent pulmonary hypertension of the newborn (PPHN) in term and near-term neonates [S1].
- LungFit® PH received European CE mark approval in November 2024 for treatment of infants with hypoxic respiratory failure associated with pulmonary hypertension and peri- and post-operative pulmonary hypertension in pediatric and adult patients [S1].
- LungFit® PH generates NO up to 400 ppm and can deliver NO continuously or for fixed times at various flow rates, with dose titration or constant dose maintenance [S1].
- The LungFit® platform aims to address severe lung infections including nontuberculous mycobacteria (NTM) lung infection and chronic obstructive pulmonary disease (COPD) [S1].
- Beyond Air has two additional programs outside the LungFit® platform: Beyond Cancer, Ltd. (80% owned) targeting solid tumors with ultra-high concentration NO delivery, and NeuroNOS Limited (84.75% owned) developing nNOS inhibitors for neurological conditions including autism spectrum disorder (ASD) [S1].
- The company initiated commercial launch of LungFit® PH in the U.S. in July 2022 and expanded commercial presence in spring 2023 [S1].
- Since CE Mark approval, Beyond Air has regulatory approvals in over 27 countries and distribution agreements covering more than 40 countries outside the U.S. [S1].
- The company submitted a PMA supplement for LungFit® PH II, a smaller, lighter, transport-ready device, to the FDA in June 2025 [S1].
- Estimated total addressable market for inhaled NO is approximately $350 million in the U.S. and $700 million or greater worldwide [S1].
- LungFit® PRO is being developed for treatment of viral community-acquired pneumonia (VCAP) including COVID-19 and bronchiolitis in infants, with clinical trials showing safety and efficacy signals [S1].
- LungFit® GO targets NTM lung infection, a rare serious pulmonary disease with increasing prevalence and high treatment costs; clinical trials are ongoing [S1].
- Financial snapshot as of September 30, 2026: cash and equivalents $5.4 million, short-term investments $5.7 million, current assets $26.6 million, current liabilities $7.3 million, current ratio 3.67, cash ratio 1.52 [S2].
- Net income for the quarter ending September 30, 2026 was a loss of $7.8 million with basic and diluted EPS of -$3.76 [S2].
- Nasdaq listing compliance has been a focus, with two 1-for-20 reverse stock splits in 2025 and 2026 to maintain minimum bid price requirements; a discretionary panel monitor is in place until August 2027 [Q0-Q3].
- Recent news highlights include narrowing Q3 loss on sales rise, FDA breakthrough device designation for LungFit GO in NTM-PD, and ongoing earnings calls providing operational updates [N1, N2, N4, N5, N7].
- Lake Street initiated coverage with a buy recommendation in September 2026 [N3].
Generated 2026-11-12
- N2
- N5
- N7
- N8
- Q0
- Q1
- Q2
- Q3
- S1 | 2026-06-26 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Beyond Air Q3 Loss Narrows On Sales Rise; Backs Sales Outlook As Next-Gen LungFit PH Awaits FDA Nod | https://www.nasdaq.com/articles/beyond-air-q3-loss-narrows-sales-rise-backs-sales-outlook-next-gen-lungfit-ph-awaits-fda
- N2 | 2026-11-12 | www.nasdaq.com | Beyond Air (XAIR) Q2 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/beyond-air-xair-q2-2027-earnings-call-transcript
- N3 | 2026-09-01 | www.nasdaq.com | Lake Street Initiates Coverage of Beyond Air (XAIR) with Buy Recommendation | https://www.nasdaq.com/articles/lake-street-initiates-coverage-beyond-air-xair-buy-recommendation
- N4 | 2026-08-31 | www.nasdaq.com | Beyond Air Receives FDA Breakthrough Device Designation For LungFit GO In NTM-PD | https://www.nasdaq.com/articles/beyond-air-receives-fda-breakthrough-device-designation-lungfit-go-ntm-pd
- N5 | 2026-08-14 | www.nasdaq.com | Beyond Air (XAIR) Q1 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/beyond-air-xair-q1-2027-earnings-call-transcript
- N6 | 2026-08-04 | www.nasdaq.com | Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum | https://www.nasdaq.com/articles/top-biotech-gainers-upc-cuts-loss-cpix-gains-ahead-q2-results-autl-builds-commercial
- N7 | 2026-06-27 | www.nasdaq.com | Beyond Air (XAIR) Q4 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/beyond-air-xair-q4-2026-earnings-call-transcript
- N8 | 2026-02-13 | www.nasdaq.com | Beyond Air XAIR Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/beyond-air-xair-q3-2026-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


